| Name | Title | Contact Details |
|---|---|---|
Justin McCue |
Chief Technology Officer | Profile |
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
CM-Tec Inc is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Clinical Resource Network is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Thermo Fisher Scientific is an American supplier of scientific instrumentation, reagents and consumables, and software services.
Enzymerx is a Paramus, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.